RESEARCH OF EFFECTIVENESS OF THE MULTIFUNCTIONAL PEP-
TIDE SUPPLEMENT REVILAB ML 04
Study period — April 2016 – November 2018
Location — Russia, Moscow, Moscow office of the Peptides
Research and Production Center of Revitalization and Health
Actual enrollment — 98 participants
Age — 42–58 y.o
Regimen — 1 capsule in the morning a.c. once in 48 hours
Period of administration — 4 months
EFFECTIVENESS OF REVILAB ML 04
Parameter Norm Placebo Placebo ML 04 ML 04
group before group after group before group after
research, research, research, research,
46 46 52 52
participants participants participants participants
Total cholesterol, 3,3–5,2 6,7±0,18 6,5±0,14 6,6±0,19 5,8±0,11*
mmol/L
C-reactive Менее 2,3±0,32 1,9±0,46 2,2±0,29 1,1±0,23*
protein, mg/l 1,0
Prothrombin 11,5–14,5 12,2±0,21 12,9±0,35 12,1±0,24 13,8±0,22*
time, c
High or unstable — 46 (100%) 42 (91%) 51 (98%) 19* (37%)
blood tension
Sleep onset — 38 (83%) 34 (74%) 44 (85%) 18* (35%)
disorder
Segment ST — 42 (91%) 41 (89%) 49 (94%) 21* (40%)
abnormality on
ECG
* Accurate changes in comparison with the placebo group.
82 // Health territory. PEPTIDES. Atherosclerosis
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.